PT -期刊文章盟又是Turcano AU -罗德里Satyadev盟盟——菲利普·蒂普顿——格里高利天TI -频率、运动障碍的分类、和时机快速进行性痴呆(好- 11.004)- 10.1212 / WNL援助。0000000000204055 DP - 2023年4月25日TA -神经病首页学第六PG - 4543 - 100 IP - 17补充2 4099 - //www.ez-admanager.com/content/100/17_Supplement_2/4543.short 4100 - //www.ez-admanager.com/content/100/17_Supplement_2/4543.full所以Neurology2023 4月25日;100 AB -目的:比较和分类运动障碍患者的快速进行性痴呆(RPD)的具体原因。背景:许多疾病与RPD同在。广义微分为临床医生提供了一个独特的挑战,必须迅速组织和解释测试提供一个及时RPD患者的临床诊断。运动障碍与几个不同的原因RPD;他们的出现、分类和发展可能提供具体RPD患者诊断的线索。设计/方法:RPD患者前瞻性的2016年2月到2022年8月在两个三级保健中心。两个神经病学家独立确定病原学诊断。第三个神经系统地回顾了研究记录识别运动障碍(如帕金森症、震颤、共济失调、肌阵挛,肌张力障碍,等等)和分类这些当礼物。RPD运动障碍之间的关系和具体的原因被认为是使用确切概率法。结果:154名患者遇到RPD标准(46.7%的女性)。 The median age-at-symptom onset was 66.0 years old (range: 18.3–84.7 years). Movement disorders were detected at presentation in 45/154 (29.2%) patients and in 73/154 (47.4%) patients at some point in the illness course. Gait disorders (n=40, 52.6%) were the most frequent movement disorder observed, followed by tremor (n=30, 40.5%), rigidity (n=24, 32.4%), ataxia (n=19, 25.7%) and myoclonus (n=19, 25.7%). Movement disorders were more commonly associated with prion disease (OR=3.65, 95% CI 1.27–11.93, p=0.008), and appeared on average 89 days after symptomatic onset. Detection of myoclonus (OR=6.80, 95%CI 2.0–22.54, p<0.005) was associated with higher odds of CJD, with average time from symptom onset to myoclonus of 118 days. Bradykinesia was associated with Alzheimer disease related dementias (OR=7.38, 95%CI 1.54–46.14, p=0.004).Conclusions: Detection and classification of movement disorders may inform etiologic diagnosis in patients with RPD.Disclosure: Dr. Turcano has nothing to disclose. Mr. Satyadev has nothing to disclose. Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Alzheimer’s Tennessee. Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Charlotte County Medical Society, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Parabon Nanolabs. The institution of Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Barrow Law. Dr. Day has stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from Chan Zuckerberg Initiative. The institution of Dr. Day has received research support from Alzheimer’s Association. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Horizon Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with American Academy of Neurology. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing Education, Inc. Dr. Day has a non-compensated relationship as a Clinical Director with AntiNMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.